In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Lexeo Therapeutics Inc (NASDAQ: LXEO) closed at $3.53 in the last session, up 7.29% from day before closing price of $3.29. In other words, the price has increased by $7.29 from its previous closing price. On the day, 0.62 million shares were traded. LXEO stock price reached its highest trading level at $3.59 during the session, while it also had its lowest trading level at $3.11.
Ratios:
We take a closer look at LXEO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.42 and its Current Ratio is at 3.42. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on June 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $28.
On June 06, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $22.
On November 28, 2023, Stifel started tracking the stock assigning a Buy rating and target price of $20.Stifel initiated its Buy rating on November 28, 2023, with a $20 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 16 ’25 when Townsend Richard Nolan sold 1,074 shares for $2.77 per share. The transaction valued at 2,979 led to the insider holds 221,173 shares of the business.
Adler Eric sold 585 shares of LXEO for $1,623 on May 16 ’25. The Chief Medical Officer now owns 67,681 shares after completing the transaction at $2.77 per share. On May 16 ’25, another insider, Robertson Jenny, who serves as the Chief Legal Officer of the company, sold 521 shares for $2.77 each. As a result, the insider received 1,445 and left with 63,098 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXEO now has a Market Capitalization of 117167408 and an Enterprise Value of 26721774.
Stock Price History:
The Beta on a monthly basis for LXEO is 0.77, which has changed by -0.7671504 over the last 52 weeks, in comparison to a change of 0.11936104 over the same period for the S&P500. Over the past 52 weeks, LXEO has reached a high of $19.50, while it has fallen to a 52-week low of $1.45. The 50-Day Moving Average of the stock is 12.99%, while the 200-Day Moving Average is calculated to be -46.75%.
Shares Statistics:
According to the various share statistics, LXEO traded on average about 966.06K shares per day over the past 3-months and 1098890 shares per day over the past 10 days. A total of 33.19M shares are outstanding, with a floating share count of 25.01M. Insiders hold about 24.67% of the company’s shares, while institutions hold 81.93% stake in the company. Shares short for LXEO as of 1745971200 were 3264722 with a Short Ratio of 3.38, compared to 1743379200 on 2579137. Therefore, it implies a Short% of Shares Outstanding of 3264722 and a Short% of Float of 11.4700004.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Lexeo Therapeutics Inc (LXEO) is currently being evaluated by 6.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.65, with high estimates of -$0.46 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$2.22 and -$3.29 for the fiscal current year, implying an average EPS of -$2.86. EPS for the following year is -$2.21, with 5.0 analysts recommending between -$1.6 and -$2.69.
